PharmaTher Holdings Ltd. is a promising life sciences company committed to marketing, development and research of drug delivery systems and ketamine to cure pain disorders, neurodegenerative and neuropsychiatric disorders. With the company’s strength, KETARX, the approval has sped up to certify in additional indications, mainly for rare disorders. The company discovers new innovative delivery methods to improve patient outcomes.
PharmaTher Holdings Ltd. Will be expanding its PharmaPatch™ microneedle patch platform into effective GLP-1 therapies to introduce new robust treatment to the weight management sector for obesity. This smart initiative is the preparation of the company to explore the obesity market, which speaks to the confidence level of the company.
Trusting its development success with ketamine and various psychedelic compounds patch programs, printed research and pre-IND fuelling work have not only unveiled the potential value of the programs but inspired the company to trust its instincts and strong start in the obesity sector.
The ketamine and psychedelic patch programs are the hope for the success of this initiative for platform expansion. The program is engineered to sustain and balance delivery and mitigate administration stress with the convincing results that contribute to the tolerability, flexibility and expanded delivery dosing volume via drug loading and patch size. PharmaTher thinks that this platform is capable of resonating with the needs and other specificities needed for GLP-1 therapies.
CEO and Founder of PharmaTher, Fabio Chianelli, said, “The company discovered this PharmaPatch™ platform to find a solution to real-world administration challenges and later deliver drugs with a patient-friendly form with the capability to help sustained drug exposure. After upgrading our ketamine and multiple psychedelic patch programs, we are now presenting this platform, taking it as an opportunity to accelerate growth in GLP-1 therapy for obesity.”
“Our major objective is to establish an at-home microneedle patch with no pain to contribute long-lasting delivery effectively for at least one month from one patch application.”
The benefits of the GLP-1 microneedle patch lie in its convenience at door step, simplifying patients’ experience, and a needle-free administration that will improve intradermal delivery. Further calculating other benefits, the company intends to conduct a preclinical assessment to elevate the GLP-1 PharmaPatch™ initiative. Latest, PharmaTher is near to confirm patent application, involving innovations increased from this program and will soon envelope the application by this month.
Mansi Kadam is a market research writer with over 3 years of experience analyzing trends in the healthcare industry. At Towards Healthcare, she covers innovations in medical sector, sustainability initiatives, and the evolving regulatory landscape.
